CENTRAL LABORATORIES WHITE PAPERS & ARTICLES

• Interpreting Early Inflammation Signals: What Early Human Data Tells Us

  Early inflammatory signals can mislead without context. Benchmarked human challenge models reveal true biological activity, guiding decisions on mechanism, dosing, and clinical development.

• Responsible AI In Clinical Trials Starts With How It Is Designed

  Explore how trials can responsibly use AI to move faster while keeping human judgment, data protections, and auditability intact.

• Why Benchmarking Inflammatory Models Matters: What Early Human Data Tells Us

  Benchmarking immune challenge models clarifies early pharmacodynamic signals, helping teams distinguish true target engagement from variability, prioritize endpoints, and make confident decisions.

• Expression Of Key Immunology Drug Targets In Human Inflammatory Challenge Models

  Human challenge models reveal immune pathway behavior in controlled settings, linking early research to outcomes and helping confirm target engagement, refine dosing, and reduce development uncertainty.

• Data Quality And Monitoring In Clinical Trials: Reducing Errors And Ensuring Compliance

  Clear data ownership and tailored reporting tools reduce errors and manual reconciliation, keeping trial data accurate and audit-ready.